Presented by:
P. Michael Ho, MD, PhD, David J. Magid, MD, MPH, Susan M. Shetterly, MS, Kari L. Olson, PharmD, BCPS, Thomas M. Maddox, MD, MSc, Pamela N. Peterson, MD, MSPH, Frederick A. Masoudi, MD, MSPH, John S. Rumsfeld, MD, PhD
6. Rates of non-adherence Non-adherent patients were younger and more likely to have COPD and depression n=10,021 n=13,596 n=11,865
7. Non-adherence to cardioprotective medications is associated with adverse outcomes 0.5 All-cause mortality n=1,889 CV mortality n=372 CV Hospitalization* n=2,008 Coronary Revascularization # n=2,117 B-blockers Statins ACE-inhibitors Hazards Ratio 1.0 2.0 *Hospitalization for AMI or heart failure #PCI or CABG
8. Non-adherence to H2 antagonists or proton pump inhibitors not associated with adverse outcomes 1.14 (0.97-1.33) All-cause mortality 1.10 (0.78-1.57) CV mortality 1.02 (0.87-1.18) CV hospitalization 1.07 (0.92-1.23) Coronary revascularization Hazard ratio (95% confidence interval) Outcome